Braveheart Bio to Participate in Cantor Global Healthcare Conference

SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Cantor Global Healthcare Conference, being held September 9-11 in New York, NY. Management will participate in a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT.

Interested parties may access a live webcast by visiting the News & Events section of the Braveheart website at https://ir.braveheart.bio/, with replays available in a temporary archive following the event.

About Braveheart Bio

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring.

Investor Relations Contact
Alexander Sharif
New Street Investor Relations
[email protected]

Media Contact
FGS Global
[email protected]  

You May Also Be Interested In

• Cantor Fitzgerald Starts Braveheart Bio (BRVE) at Overweight
• Tema Photonics & Optical ETF (LAZR) Increases Anthropic Position Ahead of Highly Anticipated IPO
• FuelCell Energy Reports Third Fiscal Quarter 2026 Results; Executes First Data Center Power Agreement, Increases Annualized Production Rate & Focuses on Capacity Expansion